Back to top

Castle Biosciences initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Castle Biosciences (CSTL) with a Buy rating and $40 price target Published first on TheFly – the ultimate source...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Castle Biosciences, Inc. (CSTL)